利用生物纳米技术改进抗体药物研发。
Improving antibody drug development using bionanotechnology.
机构信息
Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
出版信息
Curr Opin Biotechnol. 2022 Apr;74:137-145. doi: 10.1016/j.copbio.2021.10.027. Epub 2021 Dec 7.
Monoclonal antibodies are being used to treat a remarkable breadth of human disorders. Nevertheless, there are several key challenges at the earliest stages of antibody drug development that need to be addressed using simple and widely accessible methods, especially related to generating antibodies against membrane proteins and identifying antibody candidates with drug-like biophysical properties (high solubility and low viscosity). Here we highlight key bionanotechnologies for preparing functional and stable membrane proteins in diverse types of lipoparticles that are being used to improve antibody discovery and engineering efforts. We also highlight key bionanotechnologies for high-throughput and ultra-dilute screening of antibody biophysical properties during antibody discovery and optimization that are being used for identifying antibodies with superior combinations of in vitro (formulation) and in vivo (half-life) properties.
单克隆抗体被用于治疗广泛的人类疾病。然而，在抗体药物开发的早期阶段，仍有几个关键挑战需要用简单且广泛适用的方法来解决，特别是与针对膜蛋白产生抗体以及识别具有类药性生物物理特性（高溶解性和低黏度）的抗体候选物有关。在此，我们重点介绍了在不同类型的脂质体中制备功能稳定的膜蛋白的关键生物纳米技术，这些技术正被用于改进抗体发现和工程化工作。我们还重点介绍了抗体发现和优化过程中用于高通量和超低稀释筛选抗体生物物理特性的关键生物纳米技术，这些技术可用于鉴定体外（配方）和体内（半衰期）特性更优的抗体。
Zotero 插件